Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis

Si-Qian Gao, Chen Chang, Jun-Jun Li, Ying Li, Xiao-Qian Niu, Dan-Ping Zhang, Long-Jian Li and Jian-Qing Gao

ABSTRACT
Nonhealing chronic wounds on foot induced by diabetes is a complicated pathologic process. They are mainly caused by impaired neovascularization, neuropathy, and excessive inflammation. A strategy, which can accelerate the vessel network formation as well as inhibit inflammatory response at the same time, makes it possible for effective diabetic ulcers treatment. Co-delivery of multiple drugs with complementary bioactivity offers a strategy to properly treat diabetic wound. We previously demonstrated that hydroxysafflor yellow A (HSYA) could accelerate diabetic wound healing through promoting angiogenesis and reducing inflammatory response. In order to further enhance blood vessel formation, a pro-angiogenic molecular called deferoxamine (DFO) was topically co-administrated with HSYA. The in vitro results showed that the combination of DFO and HSYA exerted synergistic effect on enhancing angiogenesis by upregulation of hypoxia inducible factor-1 alpha (HIF-1α) expression. The interpenetrating polymer networks hydrogels, characterized by good breathability and water absorption, were designed for co-loading of DFO and HSYA aiming to recruit angiogenesis relative cells and upgrade wound healing in vivo. Both DFO and HSYA in hydrogel have achieved sustained release. The in vivo studies indicated that HSYA/DFO hydrogel could accelerate diabetic wound healing. With a high expression of HIF-1α which is similar to that of normal tissue. The noninvasive US/PA imaging revealed that the wound could be recovered completely with abundant blood perfusion in dermis after given HSYA/DFO hydrogel for 28 days. In conclusion, combination of pro-angiogenic small molecule DFO and HSYA in hydrogel provides a promising strategy to productively promote diabetic wound healing as well as better the repair quality.

1. Introduction
By 2030, approximately more than 489 million adults worldwide would be afflicted with diabetes (Blaktytny and Jude, 2006). There is a high mortality for diabetic patients who suffer from chronic ulcers, because these nonhealing wound on foot is the major cause of non-traumatic amputations, which carry a 50% death rate on average due to infection (Barshes et al., 2013; Wukich et al., 2013). Although many therapeutics have been proposed to improve diabetic ulcers, only a few modestly effective technologies are now clinically applied.

Diabetic ulcers have a complex pathologic process, within which a major factor leading to nonhealing wound in diabetes is the reduced neovascularization caused by hyperglycemia (Faglia et al., 2013). Rich blood flow helps transfer nutrients to the wound site and insufficient local blood perfusion at the distal part of body leads to limb ischemia and even tissue necrosis (Capla et al., 2007; Jan et al. 2013). Therefore, accelerating the vessel network formation is of importance. Nowadays, there are many vascular remodeling based researches (Cho et al., 2006; Hou et al., 2013; Kant et al., 2015; Gao et al., 2017; Wang et al., 2018). We discovered a Chinese medicine monomer could effectively accelerate wound healing mainly depends on vascular promotion (Chen et al., 2012; Shan et al., 2015; Li et al., 2017), which makes it a potential drug for trauma treatment. We also demonstrated that hydroxysafflor yellow A (HSYA), a chief bioactive compound derived from the herb Carthamus tinctorius L., could speed up diabetic wound healing through reducing inflammatory response, enhancing angiogenesis and re-epithelialization (Gao et al., 2018). But its effect on bettering the repair quality is still limited, since HSYA alone is not enough to exert angiogenesis effect on the diabetic wound healing. We tried to increase the dosage of HSYA to enhance its effect on diabetic wound healing, but the result was counterproductive (Supplementary Figure S1), which is probably because high concentration of HSYA inhibits...
angiogenesis (Wang et al., 2016). Hence, we consider synthetically combing two drugs to promote diabetic wound healing more efficiently through enhancing angiogenesis.

It has been reported that deferoxamine (DFO), a FDA-approved pro-angiogenesis small molecule, could correct the impaired HIF-1α-mediated transactivation in diabetes (Andrews, 1999). DFO can chelate iron by binding ferrous (Fe²⁺) with the hydroxy groups to prevent iron-catalyzed reactive oxygen stress (Sarkar et al., 2009), so as to prevent the degradation of HIF-1α. HIF-1α is critical in the regulation of cellular oxygen homeostasis and responses to hypoxia. In normal wound healing process, it is up-regulated to promote the expression of major angiogenesis relative cytokines, such as vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1 (SDF-1α) (Ceradini et al., 2004; Thangarajah et al., 2009; Thangarajah et al., 2010). However, the compromised function of HIF-1α in diabetes, which is induced by high glucose and reactive oxygen species (ROS), leads to impaired HIF-1α transactivation and reduced neovascularization (Duscher et al., 2015; Rabbani et al., 2017). DFO could promote diabetic ulcers repair through up-regulating the expression of HIF-1α. Therefore, we combine HSYA with DFO as a possible efficient strategy for chronic ulcers treatment to further strengthen the effects of HSYA on angiogenesis.

Since problems such as drug lost or wound infection may happen when drug solution is directly applied to the skin, we need to find a proper carrier to incorporate the drug monomer. Hydrogel is one of the most widely used dressings for diabetic wounds in clinical (Sun et al., 2011; Amin and Abdel-Raheem, 2014; Tran et al., 2011). Compared with the traditional dressings, hydrogels have interconnected pores which facilitate drug release and wound exudates absorption. Moist environment caused by hydrogels lead to accelerated granulation and re-epithelialization (Okan et al., 2007). Chitosan is a nontoxic cationic polysaccharide derived from partial N-deacetylation of chitin, possessing excellent bio-degradability, antibacterial, and hemostatic properties. These characteristics make it a potentially candidate biomaterials for tissue regeneration and wound healing (Bhattarai et al., 2010). However, chitosan hydrogels alone are limited by its unamiable surface and mechanical weakness (Park et al., 2010). To address these problems, another natural polymer - gelatin - were employed to cross-link with chitosan and also Genipin, a low toxic natural cross-linker, was used for hydrogel formation (Cui et al., 2015). Herein, we incorporated HSYA and DFO into the interpenetrating polymer networks (IPN) hydrogels fabricated by gelatin and chitosan to investigate whether it can accelerate diabetic wound healing.

2. Materials and methods
2.1. Materials

HSYA and Genipin (GP) were purchased from Shanghai Sunny Biotech Co., Ltd. (China; purity >98%, high-performance liquid chromatography (HPLC)). Deferoxamine (DFO) was obtained from Sigma-Aldrich (St.Louis, MO). Chitosan (viscosity: 100–200mPas; degree of deacetylation: >95%), gelatin type B (from bovine skin), paraformaldehyde, Triton X-100 and thiazoylblue tetrazoliumbromide (MTT) were obtained from the Sigma-Aldrich. Cell Counting Kit-8 (CCK-8) assay kit and nitric oxide (NO) assay kit were purchased from Boster, Inc. (Wuhan, China). Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ). The immortalized human keratinocytes line, human fibroblast cells, and human umbilical vein endothelial cells were obtained from the institute of Biochemistry and Cell Biology, Shanghai Institution for Biological Sciences, Chinese Academy of Science.

2.2. Animals

Six-week-old male Sprague-Dawley rats (220–240g) were applied in diabetic wound healing studies. All animals were supplied by and kept in Zhejiang University Experiment Animal Center, China. They were maintained under the condition of 25 ± 1°C with free access to standard animal food and tap water. All animal experiments were carried out according to the Zhejiang University guidelines concerning welfare of experimental animals.

2.3. In vitro studies

2.3.1. Wound scratch assay

The Culture Insert (ibidi GmbH, Martinsried, Germany) was used to create a wound in the cell culture (Zhu et al., 2015). The culture insert was placed on a 24-well plate and 70 μL of human epithelial keratinocytes (HEKs) at a concentration of 5 × 10⁵ cells/mL was added to both wells of the insert. After 24 h, the culture was wounded by removing the existing insert which leave a scratch and medium supplemented with HSYA solution and HSYA/DFO solution were added to continue the cell culture and wound healing process. All scratches were performed in triplicate. The migration of keratinocytes was photographed using an inverted microscope at 0, 60, and 96 h until gap closure was complete. The percentages of wound closure were calculated using the ImageJ software (NIH, Bethesda, MA). An increase in the percentage of the closed area demonstrated the migration of cells.

2.3.2. Tube formation assay

The Matrigel basement membrane matrix was thawed at 4 °C overnight. All pipettes and 96-well culture plates were pre-cooled before use. After coating the plates with Matrigel (50 μL/well) for 30 min at 37 °C until it solidified, medium supplemented with various concentrations of HSYA or DFO containing 1.5 × 10⁶ human umbilical vein endothelial cells (HUVECs) were seeded in each well. After 4–6 h, tube-like structures formed and calcine was continually added to the culture for 30 min. Then fluorescence was photographed by an inverted fluorescence microscope. The total tube length was quantified using the ImageJ software.

2.3.3. Cellular immunofluorescence assay

Human dermal fibroblasts were seeded in 24-well plates. After culturing in 37 °C and 5% CO₂ humidified incubator for
24 h, the cells were washed three times with PBS (pH 7.4) and then fixed with 4% paraformaldehyde for 10 min at room temperature. After permeabilized with 0.2% (v/v) Triton X-100 for 15 min, the cells were blocked with 1% bovine serum albumin (BSA) for 30 min and incubated with primary anti-HIF-1α (1:50) at 4 °C overnight. After rinsing with PBS for three times, the cells were incubated with fluorescein isothiocyanate (FITC) labeled anti-mouse IgG (1:500) for 1 h at room temperature in darkness and then counterstained with 4',6-diamidino-2-phenylindole (DAPI) for 15 min.

2.3.4. Preparation of HSYA/DFO chitosan/gelatin hydrogels
Firstly, chitosan was dissolved in deionized water containing 1% (v/v) acetic acid at room temperature to obtain a 3% (w/v) solution. Gelatin was dissolved in deionized water at 50 °C to obtain a 2.5% (w/v) solution. Then, the chitosan and gelatin were mixed in different ratio (3:7, 5:5, 7:3) and stirred for 4 h at 50 °C. The hydrogels were prepared by blending chitosan and gelatin solution with genipin (0.5%), followed by stirring for 6 h at 40 °C. HSYA and DFO were added to the hydrogel with stirring at 40 °C for homogenization (the final concentration is 2 and 0.4 mg/mL, respectively). Blank hydrogel was also prepared as the above procedure.

2.3.5. Scanning electron microscope (SEM) observation
Lyophilized hydrogels were carefully sectioned, fixed on a metal holder and coated with gold. The cross-section morphology of the hydrogel was observed by using a scanning electron microscope (JSM-5510LV, JEOL, Japan).

2.3.6. Rheology test
An R/S plus Mo8-219 rheometer (Brookfield, MA) was used to quantitatively evaluate the rheological behavior of chitosan/gelatin hydrogel by dynamically monitoring variations of hydrogel storage modulus (G′) and loss modulus (G″) as a function of frequency (Hz). HSYA-DFO loaded hydrogel was spread onto a parallel plate (diameter: 40 mm) for testing in accordance with standard practice D and the concerned parameters were evaluated at 37 °C.

2.3.7. In vitro drug release profile
The drug release study was performed using the dialysis bag method. Briefly, a dialysis bag (molecules cutoff of 8000–14,000) was required to be soaked in the release medium overnight prior to the research. The HSYA solution and HSYA-gel, placed in dialysis bags, were immersed in centrifugal tubes containing 8 ml PBS (pH7.4) at 32 °C at 100 rpm for 60 h to assure the maximum drug release. At fixed intervals, the release medium was withdrawn from the centrifugal tubes and replaced with fresh release medium to maintain the sink condition. The cumulative amount of HSYA released was determined by HPLC.

2.4. In vivo diabetic wound healing study
2.4.1. Establishment of a diabetic rat model
Six-week-old Sprague-Dawley rats (220–240g) were used for the study. After adaptive feed for two weeks, 270–300 g rats were induced for Type 1 Diabetes Mellitus (T1DM) model by a single intraperitoneal injecting streptozotocin (STZ) at 75 mg/kg. STZ was dissolved in citrate buffer (pH 4.2–4.5). Three days later, the tail vein blood glucose levels were measured. Those rats with a blood glucose level over 16.7 mmol/L were considered as diabetic rats. Their blood glucose and body weight were detected for five weeks before surgery.

2.4.2. Establishment of a diabetic wound model
Diabetic rats were randomly chosen and divided into four groups: Control (PBS), HSYA/DFO solution, blank hydrogel and HSYA/DFO hydrogel (six wounds per group). The animals were anesthetized and the hair of their backs was shaved with an electric clipper. Their skin was wiped with 70% alcohol. Then, two 1.5 cm, circular, full-thickness excisional wounds that extended through the pannicus carnosus were made on each side of the midline with a biopsy punch. Next, 1-mm-thick silicone donut-shaped splints were fixed around the wounds and positioned with 6-0 nylon sutures to prevent contraction (Chereddy et al., 2015; Wang et al., 2013).

2.4.3. In vivo diabetic wound repair experiment
HSYA (2 mg/mL), DFO (0.4 mg/mL), HSYA/DFO solution, and PBS solution (2/0.4 mg/mL) were applied at the wound site once a day. Wounds on the same mouse received different types of treatments. The rats were individually housed and digitally photographed every three days. The wound areas were quantified using Image-J software and calculated as a percentage of the initial wound areas. Then we conducted the experiment about HSYA/DFO hydrogel. There were a total of four groups: 2/0.4 mg/mL of HSYA/DFO solution, 2/0.4 mg/mL of HSYA/DFO hydrogel (the ratio of GL/CS is 5:5), PBS solution, and a blank hydrogel. HSYA/DFO hydrogel was applied once every two days.

2.4.4. Evaluation of the regenerated tissue via histology and immunofluorescence
The skin tissues harvested on day 28 were fixed in 4% buffered paraformaldehyde overnight and embedded in paraffin, then sectioned (5um) and processed for hematoxylin and eosin (HE) staining to measure granulation tissue thickness, epidermis thickness. The tissue sections were also processed for immunofluorescence staining of cluster of differentiation 31 (CD31) and HIF-1α to investigate the content of newly formed vascular. Inverted fluorescence microscope was used for photograph and Image J software was applied for quantitative analysis of the samples.
2.4.5. Blood flow measurements at the wound sites
The signals of ultrasound (US) and photoacoustic (PA) imaging signals were collected using an ultrasound imaging system (Vevo 2100; Visual Sonics, Inc., Toronto, Canada) with ultrasound array transducer (MS-250 or MS-550S; Visual Sonics, Inc.). Tunable pulsed laser systems (Premiscan; GWU, Inc. Santa Clara, CA) and Vevo LAZR; Visual Sonics, Inc.) were used to deliver photons through an optical fiber bundle. The blood perfusion from diabetic wounds at the day 28 were evaluated. While measuring, the diabetic rats were anesthetized and placed on a heating plate at 37 °C to maintain the body temperature.

2.5. Statistical analysis
Numerical data are reported as mean ± standard deviation (SD) of the mean. The statistical significance between two sets of data was calculated using a two-tail Student’s t-test. One and two way analysis of variance (ANOVA) tests were used to measure differences for experiments with multiple datasets with a Turkey test performed between groups with significant differences to correct for the multiple pair-wise comparisons. A probability (p) value < .05 was considered significant.

3. Results and discussion
3.1. Co-culture of HSYA and DFO promoted cell migration and tube formation
As shown in Figure 1, HSYA alone could dose-dependently promote cell migration (p < .05). When HSYA was co-applied with DFO, significant migration was also observed. After 24 h incubation, HEKs demonstrated nearly complete scratch gap closure (94.1 and 99%) compared with control (77.8%) (Figure 1(B)). Therefore, the presence of DFO did not affect the bioactivity of HSYA. Migration of keratinocytes is a critical step for re-epithelialization (Moura et al., 2013). Improved migration could accelerate the wound healing process.

Angiogenesis is a pivotal process for wound repair, which facilitates the delivery of oxygen, nutrients, and related growth factors to wound bed, promoting formation of granulation tissues (Martin et al., 2003). It was observed that HUVECs with addition of 0.0375/0.2 mM of HSYA/DFO formed more branched tubular structure at 6 h when compared with control (Figure 1(C)). As observed in Figure 1(C), HSYA alone (0.4 mM) significantly boosted the capillary-like structures formation (p < .05). Although lower concentration (0.2 mM) of HSYA resulted in more tube formation, the combination of low concentration of HSYA and DFO presented much stronger enhancement on tube formation than HSYA treatment alone, whose average length of complete tubes was the highest (Figure 1(D)).

HIF-1α was expressed in both the cytoplasm and nucleus according to the cellular immunofluorescence images, but the majority of HIF-1α was distributed in the nucleus (Figure 1(E)). As shown in Figure 1(F), after 24 h of culturing with HSYA/DFO, significant up-regulation of HIF-1α was observed in cells compared with control (p < .05). There was higher HIF-1α expression in 0.0375/0.2 mM HSYA/DFO groups compared with the 0.2 mM HSYA alone. In vitro experiments, we found that HSYA/DFO significantly increased tube formation and secretion of HIF-1α when compared with HSYA alone. The underlying mechanism of diabetes-induced impairments in neovascularization is a dysfunction of HIF-1α. DFO, as an iron chelator, can purely upregulate HIF-1α levels in dermal fibroblasts. High expression of HIF-1α in fibroblasts recruit more angiogenesis relative cells and secrete major angiogenesis relative cytokines (VEGF, SDF-1α) (Liu et al., 2014). VEGF and SDF-1α are essential for vascular development, which increases the proliferation and migration of endothelial cells, recruits circulating endothelial progenitor cells and improves angiogenesis, and thus leading to more vessels formation (Bergeron et al., 2003), which is beneficial for diabetic wound healing. DFO has also been reported as a direct antioxidant and can reduce the oxidative stress associated with ischemia (Sundin et al., 2000). Therefore, DFO plays a protective role during hypoxic preconditioning in brain (Prass et al., 2002) and heart tissue (Dendorfer et al., 2005) as well as in cutaneous ischemic preconditioning. In addition, it has been reported that HSYA enhance endothelial cell survival under hypoxia by up-regulating the HIF-1α-VEGF pathway (Ji et al., 2009). It means that HSYA could significantly increase the expression of VEGF through up-regulation of HIF-1α. It is consistent with that of DFO.

3.4. Preparation and characterization of chitosan/gelatin hydrogel
Exposure of diabetes ulcers to the air can rise the infection risk. Appropriate dressings are needed to prevent diabetic wound from bacterial infections and absorb wound exudates. Several technologies such as silicone-coated foam and hydrocolloids have been used to reduce the risk of ulcer formation (Dumville et al., 2013). A diabetic nonhealing wound requires repetitive treatment administration and DFO has a short biological half-life (Hom et al., 2000). However, frequent dressings may result in increased pain and irritability. To reduce application frequency and increase safety as well as maintain drug efficacy, it is ideal to design a formulation with sustained drug release. Hydrogels are widely used in the clinical treatment for diabetic wounds. They have interconnected pores which facilitate drug release and wound exudates absorption. Hydrogel with excellent biocompatibility provides extracellular matrix for cells to function well. Thus, hydrogel is considered as a suitable carrier for topical application. Herein, we made the interpenetrating polymer networks hydrogels based on gelatin and chitosan to reduce application frequency and thereby increase patient compliance and convenience.

As shown in Figure 2(A), chitosan and gelatin molecule chains permeate each other fixing by crosslinker GP, resulting in the formation of sponge-like interpenetrating polymeric networks (IPN). The crosslinked hydrogels exhibited a well-defined, three-dimensional porous structure with
interconnected pores (Figure 2(B)). These pores had orderly and thin wall, which provided surface for cells like HSFs and HEKs to attach to or proliferate. It was observed that diverse ratio of GL/CS had little influence on the size of interconnected pores (Figure 2(B)). Hydrogels that are constitute of different ratio showed no significant released profile (Figure 2(C)).

After incorporating HSYA and DFO into hydrogel, we found that the release rate of DFO was always faster than that of HSYA. It is probably because DFO has smaller molecular weight (Figure 2(D)). In Figure 2(D), Both DFO and HSYA in solution showed a burst release before 2 h which was about 97 and 84% respectively. When they were loaded in hydrogel, they achieved sustained release. DFO in hydrogels kept the initial period of fast release after 1 h (about 60–70%), then followed by sustained release in later point. And the platform period of hydrogel was achieved by 8 h while the solution happened at 4 h. HSYA in hydrogel kept the initial period of
fast release after 1 h (about 40–50%) whereas followed by sustained release until 10 h. Both HSYA and DFO in hydrogel achieved fast release at early stage, which allow the diabetic wound to be covered with plenty of drugs so that the drug can better chronic wound healing at early stage.

Rheology test has been broadly employed in the evaluation of hydrogel viscoelastic properties, with storage modulus $G'$ representing the elasticity part and loss modulus $G''$ referring to the viscosity part of hydrogel. Figure 2(E) shows the changes in storage modulus and loss modulus of HSYA/DFO hydrogel as a function frequency. It showed that HSYA/DFO hydrogel was pseudoplastic fluid and it had yielding behavior, which confirmed that drug loaded hydrogel stayed at gel phase at 37°C. Thus, it is suitable dressing that can be topically applied on the skin for diabetic ulcers treatment.
3.5. Co-loaded hydrogel accelerated wound closure in STZ-induced diabetic rats

DFO is an iron chelating agent that increases HIF-1α transcription in diabetes by eliminating iron-catalyzed ROS. It can promote wound healing and decrease tissue necrosis in the setting of diabetes. Based on the pro-angiogenesis activity of HSYA/DFO co-administration on HSFs and HUVECs, we investigated whether HSYA/DFO could enhance diabetic wound healing in rat models. In our *in vivo* experiment, a splinted rat full-thickness excisional model was used to evaluate the diabetic wound healing effects. As we know, contraction leads to rapid closure of rodent wounds, and it has been reported that unsplinted wounds in db/db mice recover two times faster than the splinted (Michaels et al., 2007). Splinting prevents rapid contracture of the wounds and allows differences in granulation tissue formation or epithelialization to be assessed accurately over time (Wang et al., 2013). Therefore, our studies used this model. As shown in Figure 3(A), the more significant enhancement effect of HSYA/DFO in chronic wound repair was observed compared with the control and HSYA alone group. It demonstrated that combined application of HSYA and DFO had a synergistic effect and that could accelerate diabetic wound healing. At the beginning, DFO was widely used in patients with Mediterranean anemia to chelate redundant Fe^{2+} in blood and spleen. Until recently, attention has been paid to its pro-angiogenesis functions in bone and soft tissue (Ihnat et al., 2000). However, the application of DFO in treating wound defects have been rarely reported. It was the first time that we found co-administration of HSYA and DFO was effective in promoting wound healing in diabetic rats.

As shown in Figure 3, at day 4, there is no significant difference in wound closure among treatment group, because the new vessels were not formed and major of relative dermal cells have not migrated into the wound site in the early condition (Sharma et al., 2018). However, at day 7, the wound closure of HSYA/DFO hydrogel reached highest, which was nearly 42.9% while PBS was 14.7%. At early stage, fast drug release is beneficial for wound healing. With fast...
release of HSYA and DFO from the hydrogel at early stage, plenty of drugs covered wounds to function well. In addition, early scarring and epithelialization provided barriers to prevent infections. The wounds treated with HSYA/DFO hydrogel were dry and easier to cause scar formation during the healing process. From the day 10 to 14, the healing rate of treatment group increased rapidly as a result of the falling off of the hard scar. The PBS-treated wounds healed completely at almost the day 32 when that happened at day 17 with HSYA/DFO hydrogel. The healing rate of HSYA/DFO solution was not as good as HSYA/DFO hydrogel. HSYA/DFO solution is easily to loss. Although there were sufficient drugs on wounds at early stage, they could be degraded in the skin quickly without new drug supplement, they have short plasma half-life (Hom et al., 2000; Jin et al., 2016). In contrast, HSYA and DFO in hydrogel could take effect continually during wound healing process due to sustained release. Although the sustained release of hydrogel is not obvious, there is less exudate at the wound site, the actual release of the drug from hydrogel is slower. In addition, the maximum drug release didn’t appear around 10 h, it was just a platform period, after which the drug could still release continually although the speed is slow. Therefore, the drug release time could be far more than 10 h. In order to maintain the effect of HSYA/DFO, we used HSYA/DFO hydrogel every two days according to the drug release while HSYA/DFO solution was used every day. In this case, the results showed the advantage of combining HSYA with DFO in hydrogel on better

Figure 4. (A) HE stained wound sections at day 28. Scale bars: 200 um. E: epidermis; GT: granulation tissue; D: dermal. (B) High power field (HPF) (40×) imaging of the center of wound granulation tissues. Scale bars, 50 um. Black arrows highlight the newly formed vascular. (C) Immuno fluorescence images for HIF-1α and CD31. Scale bars, 200um. Green: HIF-1α; Red: CD31; Blue: DAPI. (D) Granulation tissue thickness in the center of wounds. (E) Epidermis thickness in the center of wounds. *p < .05 and **p < .01 versus control (n = 6; mean ± SD).
accelerating diabetic wound repair. The healing rate reached nearly 100% in two weeks with fewer usage frequency. As high expression of HIF-1α in fibroblasts induced by combined application of HSYA and DFO continually, more angiogenesis relative cells concentrated and more vessels formed in the wound, significantly accelerating repair process. However, due to the complicated wound healing process, we can’t ensure whether this drug release is optimal, maybe slower release is better, the further study needs to be explored in the future.

3.6. Histology and immunofluorescence staining analysis

Cross-sectional analysis of histological wound sections was used to measure the thickness of new epidermis and granulation tissue at each time point. On day 28, images of histology sections taken from the center part of the wounds showed that wounds treated with PBS has not closed completely yet. So it was not covered by a layer of epidermis completely and exhibited a significantly thinner stratus lucidum and basal layer. When compared to PBS-treated wounds, the HSYA/DFO hydrogel treated wounds were covered with a uniform layer of epidermis (Figure 4(A)). It significantly improved the process of re-epithelialization, leaving proper space for new tissue growth and increased number of capillaries were observed in the dermal layer (Figure 4(A,B)). In addition, newly formed granulation tissue and epidermis were thicker and better structured than other groups, suggesting more rapid healing of the wounds when treated with HSYA/DFO hydrogel (Figure 4(D,E)).

The phenomenon that a strong HIF-1α signal in the epidermal layer of HSYA/DFO treated wounds was observed, indicating a better regenerated and more matured spinous layer. High expression of HIF-1α, which could boost the delivery of nutrients and relative cytokines in fibroblasts, induced more vessels formed in wound bed and improved diabetic wound healing (Figure 4(C)). CD31 was the specific maker of newly formed vascular. On day 28, there is a more similar vessel density and skin structure to normal tissue when treated with HSYA/DFO hydrogel. Overall, proper wound healing requires the formation of a structural and functional epithelial layer and it is mediated by keratinocytes and fibroblasts. Functional neovascularization caused by upregulation of HIF-1α could facilitate cell and nutrition transportation as well as oxygen exchange in wound bed to accelerate wound re-epithelialization. Then the wound treated HSYA/DFO hydrogel resulted in skin regeneration similar with normal skin tissue.

3.7. In vivo combined US/PA imaging to assess blood vessel formation

Diminished peripheral blood flow and decreased local neovascularization are major factors that initiate the diabetic wounds. Once wounded, impaired angiogenesis further delays the formation of granulation tissue and slows the regeneration process, leaving the wounded area vulnerable to secondary infection and additional injury (Brownlee, 2001). In this study, the microvascular network in the dermis at the wound site was visualized noninvasively via a novel technique. Combined US/PA imaging was used to monitor the blood leakage, caused by blood vessel damage, deep into the skin to the subcutaneous fat (Nam et al., 2015). It has emerged as a tool to rapidly give accurate information about wound depth and blood perfusion. Because hemoglobin can be directly visualized in PA imaging (Tan et al., 2017). There have been numerous studies to visualize and quantify blood
vessels using PA imaging for various applications. For example, noninvasive assessment of tumor vascular development using PA imaging has been demonstrated (Plumb et al., 2018) (Yang et al., 2017; 53).

Figure 5 represents the cross-sectional US and PA images at day 28 after the treatment, it can reflect the blood flow at wound site with depth-resolved structural information. In uninjured diabetic rat, there was no bleeding in the subcutaneous tissue while we could observe bleeding throughout the fat tissue. It is the normal blood flow condition of skin. As shown in Figure 5, after being treated with HSYA/DFO hydrogel for 28 days, the wound recovered completely with abundant blood perfusion in dermis. But for other groups like control, the wound was not close completely yet. There was still fluid exudation from damaged tissues and blood vessels, so blood perfusion in the injured region significantly increased. It implies the process of neovascularization involved in the tissue regeneration was not finished. In addition, HSYA/DFO solution and blank hydrogel treated group at day 28 showed fewer blood flow in dermis and their blood perfusion was mainly focus on epidermis. Although there was no significant difference in wound healing rate between HSYA/DFO hydrogel and HSYA/DFO solution group, the quality of wound repair was better when treated with HSYA/DFO hydrogel.

4. Conclusions

Re-establishment of the vessel network is very important in the early stage of wound healing in diabetic diseases. In this article, instead of treatment with single drug, we developed the IPN hydrogels for co-loading of HSYA and DFO. We aimed to make use of pro-angiogenesis activity of DFO to enhance the effect of HSYA on wound healing. Specifically, co-administration of DFO and HSYA could promote angiogenesis and up-regulate HIF-1α secretion when compared with using single drug. Moreover, HSYA/DFO hydrogel treated rat exhibited a significantly enhanced tissue regeneration that is more similar to the normal skin. This study for the first time demonstrated co-administration of HSYA and DFO was more effective in promoting wound healing in diabetic rats. Because HSYA and DFO are FDA-approved, this co-loaded hydrogel delivery system is promising for treating diabetic ulcers in clinical.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This research was supported by National Key R&D Program of China (No. 2017YFE0102200) and Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.

References

Amin MA, Abdel-Raheem IT. (2014). Accelerated wound healing and anti-inflammatory effects of physically cross-linked polyvinyl alcohol-chitosan hydrogel containing honey bee venom in diabetic rats(J). Arch Pharm Res 37:1016–31. Andrews NC. (1999). Disorders of iron metabolism. N Engl J Med 341:1986–95. Bashees NR, Sigireddi M, Wrobel JS, et al. (2013). The system of care for the diabetic foot: objectives, outcomes, and opportunities. Diabet Foot Ankle 4:21847. Bergeron RJ, Wiegand J, Mcmanis JS, et al. (2003). Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency. J Med Chem 46:1470–7. Bhattachar N, Gunn J, Zhang MQ. (2010). Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 62:83–99. Blaknyr N, Jude E. (2006). The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 23:594–608. Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–20. Capla JM, Grogan RH, Callaghan MJ, et al. (2007). Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia(J). Plast Reconstr Surg 119:59–70. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1(J). Nat Med 10:858–64. Chen X, Peng LH, Li N, et al. (2012). The healing and anti-scar effects of astragaloside IV on the wound repair in vitro and in vivo. Ethnopharmacol 139:721–7. CHEREDDY KK, LOPES A, KOUSSOROPLIS S, et al. (2015). Combined effects of PLGA and vascular endothelial growth factor promote the healing of non-diabetic and diabetic wounds. Nanomedicine 11:1975–84. Cho CH, Sung HK, Kim KT, et al. (2006). COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci USA 103:4946. Cui L, Xiong ZH, Guo Y, et al. (2015). Fabrication of interpenetrating polymer network chitosan/gelatin porous materials and study on dye adsorption properties. Carbohydr Polym. 132:330–33. Dendorfer A, Heidbreder M, Hellwig-burgel T, et al. (2005). Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic Biol Med 38:117–24. Dumville JC, Deshpande S, O’meara S, et al. (2013). Foam dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev. 6:CD009911. Duscher D, Neoftou E, Wong VW, et al. (2015). Transdermal deferoxamine prevents pressure-induced diabetic ulcers. Proc Natl Acad Sci USA 112:94–9. Faglia E, Clerici G, Caminiti M, et al. (2013). Influence of osteomyelitis location in the foot of diabetic patients with transtibial amputation. Foot Ankle Int 34:2222–7. Ge SQ, Chang C, Niu XQ, et al. (2018). Topical application of hydroxy-safflor yellow A accelerates the wound healing in streptozotocin induced T1DM rats(J). Eur J Pharmacol 823:72–8. Gao WD, Jin WW, Li YN, et al. (2017). A highly bioactive bone extracellular matrix biomimetic nanofibrous system with rapid angiogenesis promotes diabetic wound healing. J Mater Chem B 5:7285–96. Hom DB, Goding GS, JR, Price JA, et al. (2000). The effects of conjugated deferoxamine in porcine skin flaps. Head Neck 22:579–84. Hou ZJ, Nie CL, Si ZX, et al. (2013). Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1 alpha. Diabetes Res Clin Pract 101:62–71. Ihnat PM, Vennerstrom JL, Robinson DH. (2000). Synthesis and solution properties of deferoxamine amides. J Pharm Sci 89:1525–36. Jan YK, Shen S, Foreman RD, et al. (2013). Skin blood flow response to locally applied mechanical and thermal stresses in the diabetic foot. Microvasc Res 89:40–6. JI DB, Zhang LY, Li CL, et al. (2009). Effect of hydroxy-safflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascul Pharmacol 50:137–45. Jin Y, Wu L, Tang Y, et al. (2016). UFLC-Q-TOF/MS based screening and identification of the metabolites in plasma, bile, urine and feces of normal and blood stasis rats after oral administration of...
hydroxysafflor yellow A. J Chromatogr B Analyt Technol Biomed Life Sci. 1012-1013:124–9.
Kant V, Gopal A, Kumar D, et al. (2015). Curcumin-induced angiogenesis hastens wound healing in diabetic rats. J Surg Res 193:978–88.
Li LJ, Gao SQ, Peng LH, et al. (2017). Evaluation of efficacy of aloin in treating acute trauma in vitro and in vivo. Biomed Pharmacother 88:1211–9.
Liu Y, She LH, Wang XY, et al. (2014). Expansion of myeloid-derived suppressor cells from peripheral blood decreases after 4-week antiviral treatment in patients with chronic hepatitis C. Int J Clin Exp Med 7:998–1004.
Martin A, Komada MR, Sane DC. (2003). Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23:117–45.
Michaels JT, Churgin SS, Blechman KM, et al. (2007). db/db mice exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted excisional wound model. Wound Repair Regen 15:665–70.
Moura LF, Dias AMA, Carvalho E, et al. (2013). Recent advances on the development of wound dressings for diabetic foot ulcer treatment-A review. Acta Biomater 9:7093–114.
Nam SY, Chung E, Suggs LJ, et al. (2015). Combined ultrasound and photoacoustic imaging to noninvasively assess burn injury and selectively monitor a regenerative tissue-engineered construct. Tissue Eng Part C Methods 21:557–66.
Okan D, Woo K, Ayello EA, et al. (2007). The role of moisture balance in wound healing[J]. Adv Skin Wound Care 20:39–53. Quiz 53–35.
Park KM, Shin YM, Joung YK, et al. (2010). In situ forming hydrogels based on tyramine conjugated 4-Arm-PPO-PEO via enzymatic oxidative reaction. Biomacromolecules 11:706–12.
Plumb AA, Huynh NT, Guggenheim J, et al. (2018). Rapid volumetric photoacoustic tomographic imaging with a Fabry-Perot ultrasound sensor depicts peripheral arteries and microvascular vasomotor responses to thermal stimuli. Eur Radiol 28:1037–45.
Prass K, Ruscher K, Karsch M, et al. (2002). Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22:520–5.
Rabbani PS, Zhou A, Borab ZM, et al. (2017). Novel lipoproteoplex delivery of Keap1 siRNA based gene therapy to accelerate diabetic wound healing. Biomaterials 132:1–15.
Sarkar K, Fox-Talbot K, Steenbergen C, et al. (2009). Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice[J]. Proc Natl Acad Sci USA 106:18769–74.
Shan YH, Peng LH, Liu X, et al. (2015). Silk fibroin/gelatin electrospun nanofibrous dressing functionalized with astagrasolide IV induces healing and anti-scar effects on burn wound. Int J Pharm 479:291–301.
Sharma A, Tate M, Mathew G, et al. (2018). Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol 9:114.
Sun G, Zhang X, Shen YI, et al. (2011). Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. Proc Natl Acad Sci USA 108:20976–81.
Sundin BM, Hussein MA, Glasofer S, et al. (2000). The role of allopurinol and deferoxamine in preventing pressure ulcers in pigs. Plast Reconstr Surg 105:1408–21.
Tan Y, Xia K, Ren Q, et al. (2017). Three-dimensional photoacoustic imaging via scanning a one dimensional linear unfocused ultrasound array. Opt Express 25:8022–8.
Thangarajah H, Vial IN, Grogan RH, et al. (2010). HIF-1alpha dysfunction in diabetes. Cell Cycle 9:75–9.
Thangarajah H, Yao DC, Chang EI, et al. (2009). The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106:13505–10.
Tran NQ, Joung YK, Lih E, et al. (2011). In situ forming and rutin-releasing chitosan hydrogels as injectable dressings for dermal wound healing. Biomacromolecules 12:2872–80.
Wang CG, Wang QQ, Gao WD, et al. (2018). Highly efficient local delivery of endothelial progenitor cells significantly potentiates angiogenesis and full-thickness wound healing. Acta Biomater 69:156–69.
Wang J, Wang JJ, Wang XX, et al. (2016). Molecular mechanism of inhibition of the abnormal proliferation of human umbilical vein endothelial cells by hydroxysafflor-yellow A. Pharm Biol 54:1800–7.
Wang XS, Ge JF, Tredget EE, et al. (2013). The mouse excision wound splinting model, including applications for stem cell transplantation. Nat Protoc 8:302–9.
Wukich DK, Armstrong DG, Attinger CE, et al. (2013). Inpatient management of diabetic foot disorders: a clinical guide. Diabetes Care 36:2862–71.
Yang L, Cheng J, Chen Y, et al. (2017). Phase-transition nanodroplets for real-time photoacoustic/ultrasound dual-modality imaging and photothermal therapy of sentinel lymph node in breast cancer. Sci Rep 7:45213.
Zhu T, Park HC, Son KM, et al. (2015). Effects of dimethylxalylglycine on wound healing of palatal mucosa in a rat model. BMC Oral Health 15:60–8.